Evidence map›Paper›PMID 39222374›Full record

ArticleCancer science2024

Crosstalk between GBP2 and M2 macrophage promotes the ccRCC progression.

Wei Zheng, Shujiang Ye, Bin Liu, Dan Liu, Ruyu Yan, Hongjuan Guo, Hongtao Yu, Xudong Hu, Huaiming Zhao, Kecheng Zhou and 1 more

Abstract read
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wei ZhengDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Shujiang YeDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Bin LiuDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Dan LiuCancer Metabolism Laboratory, School of Life Sciences, Anhui Medical University, Hefei, China.
Ruyu YanDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Hongjuan GuoCancer Metabolism Laboratory, School of Life Sciences, Anhui Medical University, Hefei, China.
Hongtao YuCancer Metabolism Laboratory, School of Life Sciences, Anhui Medical University, Hefei, China.
Xudong HuDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Huaiming ZhaoDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Kecheng ZhouCancer Metabolism Laboratory, School of Life Sciences, Anhui Medical University, Hefei, China.ORCID https://orcid.org/0000-0003-1753-2524
Guangyuan LiDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID https://orcid.org/0000-0002-3776-4261

Funding

Anhui Medical University School Foundation 2022xkj210Health Commission of Anhui Province AHWJ2022a033National Natural Science Foundation of China 32100623Scientific Research Foundation of Anhui Academy of Translational Medicine 2021zhyx-C73
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) represents a highly heterogeneous kidney malignancy associated with the poorest prognosis. The metastatic potential of advanced ccRCC tumors is notably high, posing significant clinical challenges. There is an urgent imperative to develop novel therapeutic approaches to address ccRCC metastasis. Recent investigations indicated a potential association between GBP2 and tumor immunity. However, the precise functional role of GBP2 in the progression of ccRCC remains poorly understood. The present study revealed a strong correlation between GBP2 and M2 macrophages. Specifically, our findings demonstrated that the inhibition of GBP2 significantly impedes the migratory and invasive capabilities of ccRCC cells. We observed that the presence of M2 macrophages can reverse the effects of GBP2 knockdown on tumor cell migration and invasion. Mechanistically, we demonstrated that M2 macrophages promote the expression of the GBP2/p-STAT3 and p-ERK axis in tumor cells through the secretion of interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), thereby substantially enhancing the migratory and invasive capacities of the tumor cells. Simultaneously, we have identified that GBP2 promotes the polarization of macrophages to the M2 phenotype by stimulating the secretion of interleukin-18 (IL-18). In summary, our investigation anticipates that the GBP2/IL-18/M2 macrophages/IL-10 and the TGF-β/GBP2, p-STAT3, p-ERK loop plays a crucial role in ccRCC metastasis. The collective findings from our research underscore the significant role of GBP2 in tumor immunity and emphasize the potential for modulating GBP2 as a promising therapeutic strategy for targeting ccRCC metastasis.

Indexed as

Carcinoma, Renal CellCell MovementDisease ProgressionKidney NeoplasmsMacrophagesAnimalsCell Line, TumorGTPase-Activating ProteinsGTP-Binding ProteinsHumansInterleukin-10Interleukin-18MiceNeoplasm InvasivenessSTAT3 Transcription FactorTransforming Growth Factor betaGBP2 protein, humanGTPase-Activating ProteinsGTP-Binding ProteinsIL10 protein, humanInterleukin-10Interleukin-18STAT3 protein, humanSTAT3 Transcription FactorTransforming Growth Factor betaccRCCGBP2IL‐10IL‐18M2 macrophagemetastasisTGF‐β

Identifiers

PMID39222374
PMCPMC11531969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.